Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Darlifarnib · KO-2806

Small molecule · Inhibitor of farnesyl transferase (FNTA) · developed by Kura Oncology

Phase 1 Most advanced trial
KURA Developer
1 Registered trials

What is Darlifarnib?

Darlifarnib is an orally bioavailable farnesyl transferase inhibitor. By blocking farnesylation of proteins, it prevents activation of Ras oncogenes and inhibits Ras-dependent signaling in tumor cells. It is being studied in solid tumors with HRAS alterations, including non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma and renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KO-2806
Drug type
Small molecule
Targets
farnesyl transferase (FNTA), HRAS (biomarker)
Mechanism
Inhibitor of farnesyl transferase (FNTA)
Pathways
Ras protein farnesylation, Ras-dependent signaling
Therapy area
Oncology
Developer
Kura Oncology, Inc. (KURA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
9PE5MSX2YS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06026410 Phase 1 Solid Tumors With HRAS Alterations Recruiting KURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clear Cell Renal Cell Carcinoma (ccRCC)Colorectal Cancer (CRC)Non Clear Cell Renal Cell Carcinoma (nccRCC)Non Small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Renal Cell Carcinoma (Kidney Cancer)Solid Tumors With HRAS Alterations

Other drugs acting on FNTA

More from Kura Oncology

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KURA page.

Follow KURA, the company behind Darlifarnib

See KURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KURA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.